Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03845218 · ClinicalTrials.gov registry record

Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

A clinical trial, sponsored by National Eye Institute (NEI).

Completed
Registry status
49
Enrollment target

NCT03845218 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 49 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03845218 has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
49 participants
Enrollment target

Study Summary

Background: Retinitis pigmentosa (RP) is a group of blinding eye diseases. It is caused mostly by mutations in photoreceptor-expressed genes. RP affects about 2 million people globally. There is no cure, but treatment and diagnosis can be guided by certain tests. Researchers want to see how well these tests capture stages of RP. Objectives: To find out how well certain tests track changes in retinitis pigmentosa. Eligibility: People ages 12 and older with RP Healthy volunteers ages 18 and older with no evidence of RP Design: Participants will be screened in another protocol. Participants will have 2 visits about 6 weeks apart. Both will include all the tests below. Each visit will last 5-6 hours, or a visit can be split into 2 days. Participants will give their medical and eye history. Participants will have an eye exam. Their pupils will be dilated with eye drops. Participants will give blood samples. Pictures of participants retinas will be taken. Their retinas will be measured. Participants will take several eye tests. They will: Sit in a dark room and press a button when they see lights. View a bright background then press a button when they see lights. Look into a bowl and press a button when they see lights. Sit in the dark with their eyes patched. Then they will take eye-numbing drops and wear contacts as lights flash. A small electrode taped to their forehead will record signals from their retinas. Minors will give written consent to stay in the study when they turn 18. After the study ends, they may also be asked to give consent for researchers to continue to use their study information.

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2019-09-27
Est. Completion 2023-07-19

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT03845218

The ClinicalTrials.gov registry entry for NCT03845218 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT03845218 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03845218 about?

NCT03845218 is a clinical study titled "Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures". Background: Retinitis pigmentosa (RP) is a group of blinding eye diseases. It is caused mostly by mutations in photoreceptor-expressed genes. RP affects about 2 million people globally. There is no cure, but treatment and diagnosis can be guided by certain tests. Researchers want to see how well th...

What is the current status of trial NCT03845218?

This trial is currently completed. The enrollment target is 49 participants. The study started on 2019-09-27. Estimated completion is 2023-07-19.

Who is sponsoring clinical trial NCT03845218?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.